Initial research suggested that INCB3619 could obstruct the release of the HER3 ligand heregulin in non-small cell lung cancer (NSCLC) models, which in turn enhanced the effectiveness of gefitinib. Here, ERBB3 is linked to non-small cell lung carcinoma.